tezepelumab · Tezspire
Monoclonal antibody
Also known as MEDI9929
Evidence outlook
Approved: Asthma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Chronic Obstructive Pulmonary Disease · Phase 3Eosinophilic Esophagitis · Phase 3
Also approved (4)
- Add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)
- Treatment of bronchial asthma (for use only in patients with severe or intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies)
- AsthmaTezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. Chronic rhinosinusitis with nasal polyps (CRSwNP) Tezspire is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control.
- Asthma TEZSPIRE (tezepelumab injection) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma. TEZSPIRE is not indicated for relief of acute bronchospasm or status asthmaticus (7. Warnings and Precautions). Chronic rhinosinusitis with nasal polyps (CRSwNP) TEZSPIRE is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe CRSwNP inadequately controlled by systemic corticosteroids and/or surgery.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NAVIGATOR NCT03347279 · Asthma This was a large randomized, double-blind, placebo-controlled trial with 1,061 participants. Both prespecified primary clinical endpoints were met: tezepelumab significantly reduced annual asthma exacerbations overall and in the lower-eosinophil subgroup, with p<0.001 for each comparison. Registry: NCT03347279 | 3 | Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.); Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uL (From randomisation to Study Week 52.) 2020-09-08 | Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39) | Reliable signal | link ↗ |
View 4 more trials
PATH-HOME NCT03968978 · Asthma PATH-HOME randomised 216 adolescents and adults with severe asthma 1:1 to two open-label devices that both deliver tezepelumab 210 mg. Its primary endpoint is successful self- or clinic administration by device type, with no placebo arm and no efficacy outcome, so it is a device-usability study, not efficacy evidence for asthma. Registry: NCT03968978 | 3 | Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type (Week 0, Week 4, Week 8, Week 12, Week 16, Week 20) 2020-06-05 | Successful administration (proportion of administrations, weeks 0 to 20, in clinic and at home): pre-filled syringe 95.4% to 100%; autoinjector 97.1% to 100%. No between-device hypothesis test. | Weak signal | link ↗ |
SOURCE NCT03406078 · Asthma This was a randomized, double-blind, placebo-controlled trial with 150 participants (74 receiving tezepelumab and 76 placebo). The clinical primary endpoint was not met: the proportional-odds analysis of corticosteroid-dose reduction gave an odds ratio of 1.28 (95% CI 0.69–2.35; p=0.434), so the results provide meaningful but inconclusive evidence. Registry: NCT03406078 | 3 | Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48) 2020-09-25 | Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 | Partial signal | link ↗ |
DIRECTION NCT03927157 · Asthma Registry: NCT03927157 | 3 | Annual Asthma Exacerbation Rate (AERR) (Randomization to Week 52) 2024-05-24 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
NCT02054130 NCT02054130 · Asthma The study was randomized, double-blind, and placebo-controlled, with 584 participants and a hard clinical primary endpoint measuring asthma exacerbations; all three dose comparisons met that endpoint statistically. It is graded moderate because the available record does not report a primary-endpoint power or sample-size calculation, so adequate powering cannot be confirmed. Registry: NCT02054130 | 2 | Annualized Asthma Exacerbation Rate (AER) Through Week 52 (Week 0 (Day 1) up to Week 52) 2016-12-12 | Annualized Asthma Exacerbation Rate (AER) Through Week 52 (Week 0 (Day 1) up to Week 52): Placebo 0.72 events per person-year (95% CI 0.59 to 0.88) | MEDI9929 70 mg 0.27 events per person-year (95% CI 0.19 to 0.38) | MEDI9929 210 mg 0.2 events per person-year (95% CI 0.13 to 0.3) | MEDI9929 280 mg 0.23 events per person-year (95% CI 0.16 to 0.34) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other TSLP drugs
Felcorekibart, Ocankitug, WIN378, Bosakitug, Sunakiment and 3 more. Compare all 9 TSLP drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tezepelumab (Tezspire): this drug | Approved | Monoclonal antibody | TSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizing | Reliable signal | NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39) NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed | |
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Albuterol (Ventolin) | Approved | Small molecule | Beta-2 adrenergic receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor | Reliable signal | NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056 | |
| Albuterol Sulfate (Amphastar) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Albuterol Sulfate (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | not yet graded | No reviewed efficacy summary in this indication | |
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results). | |
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow) | ApprovedUS marketing discontinued | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | No reviewed efficacy summary in this indication | |
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | Reliable signal | NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24) NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001). | |
| Budesonide (Pulmicort) | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide (Pulmicort Flexhaler) | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | Partial signal | NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027). | |
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | Partial signal | NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014) NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015) | |
| Ciclesonide (Alvesco) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis | |
| Depemokimab | Approved | Monoclonal antibody | IL-5 | Partial signal | NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58) | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414). | |
| Fluticasone Furoate (Arnuity Ellipta) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411) | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321) | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Reliable signal | NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998) | |
| Fluticasone Propionate | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate / Salmeterol (Advair Diskus) | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor | Partial signal | NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed | |
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved | Combination | Glucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor | Partial signal | NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) | |
| Levalbuterol (Xopenex HFA) | Approved | — | beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Mepolizumab (Nucala) | Approved | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | Weak signal | NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66 NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale) | Approved | Small molecule | Glucocorticoid receptor; Beta-2 adrenergic receptor | Partial signal | NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001. NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001. | |
| Montelukast (Singulair) | Approved | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) | Weak signal | NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin. | |
| Omalizumab (Xolair) | Approved | Monoclonal antibody | IgE (immunoglobulin E), IgE | Weak signal | No reviewed efficacy summary in this indication | |
| Primatene Mist | Approved | Small molecule | Adrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselective | Partial signal | NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64). | |
| Salmeterol (DISKUS) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Terbutaline | Approved | Small molecule | Beta-2 adrenergic receptor (ADRB2) | not yet graded | No reviewed efficacy summary in this indication | |
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Reliable signal | NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5) | |
| Beclomethasone Dipropionate / Formoterol Fumarate | Phase 3 | Small molecule | Glucocorticoid receptor; β2-adrenergic receptor | Reliable signal | NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206) | |
| Felcorekibart | Phase 3 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Fenoterol | Phase 3 | Small molecule | Beta-2 adrenergic receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Fenoterol / Ipratropium Bromide | Phase 3 | Small molecule | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptor | Reliable signal | NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo. | |
| Indacaterol Maleate / Mometasone Furoate | Phase 3 | — | Glucocorticoid receptor / Beta-2 adrenergic receptor | Partial signal | NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016) NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134) | |
| Ipratropium | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | Weak signal | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | Partial signal | NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010) NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL | |
| Ocankitug | Phase 3 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Oxitropium Bromide (Ba253BINEB) | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | Weak signal | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Salbutamol HFA-152a | Phase 3 | Small molecule | Beta-2 adrenergic receptor | Weak signal | NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Vilanterol | Phase 3 | Small molecule | Beta-2 adrenergic receptor | Partial signal | NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) | |
| Glycopyrronium (PT001) | Phase 2/3 | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) | |
| Stapokibart | Phase 2/3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| WIN378 | Phase 2/3 | Monoclonal antibody | TSLP | Weak signal | Featured results are safety only in this race | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-RAGE | Phase 2 | RNA / oligonucleotide | RAGE (receptor for advanced glycation end-products) | Weak signal | Featured results are safety only in this race | |
| Bosakitug | Phase 2(overall) | Monoclonal antibody | TSLP | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| ENV-294 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Freneslerbart / Mevonlerbart | Phase 2 | Monoclonal antibody | Fel d 1 (major cat allergen protein) | Reliable signal | NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083 | |
| Frevecitinib | Phase 2 | Small molecule | JAK1/2/3/TYK2 | Weak signal | No reviewed efficacy summary in this indication | |
| KT-621 | Phase 2 | Small molecule | STAT6 | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 2 | Antibody-derived scaffold | TSLP + IL-13 | Weak signal | Featured results are safety only in this race | |
| PBF-680 | Phase 2 | — | Adenosine A1 receptor | Partial signal | NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1) | |
| Quisovalimab | Phase 2 | Monoclonal antibody | LIGHT (TNFSF14) | Partial signal | NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed | |
| RC1416 | Phase 2 | Multispecific antibody | IL-4 / IL-5 / IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilzabrutinib | Phase 2 | Small molecule | BTK | Partial signal | NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed | |
| Sunakiment | Phase 2 | Antibody fragment | TSLP | Partial signal | Featured results are safety only in this race | |
| Tozorakimab | Phase 2 | Monoclonal antibody | IL-33 | Partial signal | NCT04570657: Change from baseline to week 16 in clinic pre-bronchodilator FEV1 vs placebo (LSMD, 80% CI): tozorakimab 600 mg +4 mL (-71 to 79), p=0.473; tozorakimab 300 mg +36 mL (-38 to 111), p=0.267 missed | |
| Umeclidinium (Incruse Ellipta) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT01573624: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) NCT01641692: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) (Day 15 of each treatment period (up to Study Day 71)): All Study Treatments — Theta1 (mean Baseline): 0.0363 unitless (95% CI 0.028 to 0.045); Theta2 (period Baseline): -0.97 unitless (95% CI -1.06 to -0.881); Omega (mean Baseline): 0.00371 unitless (95% CI 0.002 to 0.005); Omega (period Baseline): 0.149 unitless (95% CI 0 to 0.298); Sigma (Variance of Residual error): 0.0393 unitless (95% CI 0.028 to 0.05) | |
| Verekitug | Phase 2 | Monoclonal antibody | TSLP receptor | Reliable signal | NCT06196879: Annualized Asthma Exacerbation Rate (AAER) reduction vs placebo (VALIANT): -56% at verekitug 100 mg q12w (p<0.0003); -39% at 400 mg q24w (p<0.02) | |
| GR2002 | Phase 1(overall) | Multispecific antibody | TSLP | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SKB575 | Phase 1 | Multispecific antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-333 | —(overall) | Undisclosed | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Itepekimab | Discontinued | Monoclonal antibody | IL-33 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 70 furthest-along competitors are listed; 19 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tezspire (tezepelumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (3)
January 2027 (1)
What to watch
2028 (4)
January 2028 (1)
What to watch
February 2028 (1)
March 2028 (1)
What to watch
May 2028 (1)
2029 (5)
January 2029 (1)
What to watch
March 2029 (2)
May 2029 (1)
What to watch
August 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent